Cargando…
Casirivimab - Imdevimab in Covid 19 – Early Indian experience
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Tuberculosis Association of India. Published by Elsevier B.V.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489261/ https://www.ncbi.nlm.nih.gov/pubmed/35760489 http://dx.doi.org/10.1016/j.ijtb.2021.09.014 |
| _version_ | 1784578317052018688 |
|---|---|
| author | Venkitakrishnan, Rajesh Augustine, Jolsana Ramachandran, Divya Cleetus, Melcy |
| author_facet | Venkitakrishnan, Rajesh Augustine, Jolsana Ramachandran, Divya Cleetus, Melcy |
| author_sort | Venkitakrishnan, Rajesh |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8489261 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Tuberculosis Association of India. Published by Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84892612021-10-04 Casirivimab - Imdevimab in Covid 19 – Early Indian experience Venkitakrishnan, Rajesh Augustine, Jolsana Ramachandran, Divya Cleetus, Melcy Indian J Tuberc Correspondence Tuberculosis Association of India. Published by Elsevier B.V. 2022-07 2021-10-04 /pmc/articles/PMC8489261/ /pubmed/35760489 http://dx.doi.org/10.1016/j.ijtb.2021.09.014 Text en © 2021 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Venkitakrishnan, Rajesh Augustine, Jolsana Ramachandran, Divya Cleetus, Melcy Casirivimab - Imdevimab in Covid 19 – Early Indian experience |
| title | Casirivimab - Imdevimab in Covid 19 – Early Indian experience |
| title_full | Casirivimab - Imdevimab in Covid 19 – Early Indian experience |
| title_fullStr | Casirivimab - Imdevimab in Covid 19 – Early Indian experience |
| title_full_unstemmed | Casirivimab - Imdevimab in Covid 19 – Early Indian experience |
| title_short | Casirivimab - Imdevimab in Covid 19 – Early Indian experience |
| title_sort | casirivimab - imdevimab in covid 19 – early indian experience |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489261/ https://www.ncbi.nlm.nih.gov/pubmed/35760489 http://dx.doi.org/10.1016/j.ijtb.2021.09.014 |
| work_keys_str_mv | AT venkitakrishnanrajesh casirivimabimdevimabincovid19earlyindianexperience AT augustinejolsana casirivimabimdevimabincovid19earlyindianexperience AT ramachandrandivya casirivimabimdevimabincovid19earlyindianexperience AT cleetusmelcy casirivimabimdevimabincovid19earlyindianexperience |